NDA 211759 · Carwin Pharm Assoc
Vyscoxa
Celecoxib · Oral · Nonsteroidal Anti-inflammatory Drug
Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 29, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
631
125 Phase 3, 38 recruiting
FAERS reports
35,685
26,846 serious, 6,053 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. ( 5.1 ) • VYSCOXA is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. ( 4 , 5.1 ) • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer...
What it is approved for
From the label in effect Jul 31, 2025.
1. INDICATIONS AND USAGE VYSCOXA is indicated In adults for the management of the signs and symptoms of: VYSCOXA contains celecoxib, a nonsteroidal anti-inflammatory drug, and is indicated: In adults for • Osteoarthritis (OA) ( 1.1 ) • Rheumatoid Arthritis (RA) ( 1.2 ) • Ankylosing Spondylitis (AS) ( 1.3 ) In pediatric patients two years and older for • Juvenile Rheumatoid Arthritis (JRA) ( 1.4 ) Limitations of Use VYSCOXA must be administered on an empty stomach at least 2 hours before or 1 hour after food. Taking VYSCOXA with food results in plasma exposures of celecoxib up to 50% higher than intended. If patients cannot tolerate VYSCOXA in the fasted state, discontinue use of VYSCOXA ( 2.1 , 5 , 12 ) 1.1 Osteoarthritis (OA) [ see Clinical Studies (14.1) ]. 1.2 Rheumatoid Arthritis (RA) [ see Clinical Studies (14.2) ]. 1.3 Ankylosing Spondylitis (AS) [ see Clinical Studies (14.3) ]. In pediatric patients two years of age and older for the management of the signs and symptoms of: 1.4 Juvenile Rheumatoid Arthritis (JRA) [ see Clinical Studies (14.4) ]. Limitations of Use VYSCOXA must be administered on an empty stomach at least 2 hours before or 1 hour after food. Taking VYSCOXA with food results in plasma exposures of celecoxib up to 50% higher than intended. If patients cannot tolerate VYSCOXA in the fasted state, discontinue use of VYSCOXA (reference Sections 2.1 , 5 , 12 ). VYSCOXA is NOT indicated for the management of acute pain or treatment of primary dysmenorrhea.
Mechanism: Celecoxib has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. Celecoxib is a potent inhibitor of prostaglandin synthesis in vitro . Celecoxib concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 29, 2025 Original approval · Type 3 - New Dosage Form LabelMedication GuideLetter
1 products under this application
- VYSCOXA · CELECOXIB 10MG/ML · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Celecoxib" as an intervention, any sponsor and status, largest first.
- Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00346216 · 24,081 participants · Start Oct 4, 2006 · Primary completion Apr 12, 2016
Drug: celecoxib; Ibuprofen and 1 more · For: Arthritis, Rheumatoid
Sites: Alabaster, Alabama; Bessemer, Alabama; Birmingham, Alabama · 1,066 sites in all
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)Pivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00373685 · 8,067 participants · Start Oct 2006 · Primary completion Nov 2010
Drug: Celecoxib; Any commercially available NSAID with the indication for osteoarthritis · For: Osteoarthritis
Sites: Abbeville, Alabama; Alexander City, Alabama; Bay Minette, Alabama · 777 sites in all
- The Standard Care Versus Celecoxib Outcome TrialPivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT00447759 · 7,297 participants · Start Jun 2007 · Primary completion Aug 2015
Drug: Celecoxib; Diclofenac · For: Osteoarthritis; Rheumatoid Arthritis
Sites: Odense, Denmark; Zeist, Netherlands; Aberdeen, United Kingdom · 10 sites in all
- Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With ArthritisPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00141102 · 4,484 participants · Start Oct 2005 · Primary completion May 2009
Drug: Celecoxib; Diclofenac + Omeprazole · For: Osteoarthritis; Arthritis, Rheumatoid
Sites: Genk, Belgium; Ghent, Belgium; Hasselt, Belgium · 194 sites in all
NovartisNovartis (NVS)
NCT00145301 · 3,036 participants · Start Sep 2004 · Primary completion Nov 2005
Drug: Lumiracoxib · For: Osteoarthritis
Sites: Nuremberg, Germany
- Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or KneePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02528188 · 3,021 participants · Start Jul 21, 2015 · Primary completion Oct 5, 2018
Drug: NSAID; Tanezumab 2.5 mg and 1 more · For: Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 507 sites in all
- Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or HipPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT00809354 · 2,720 participants · Start Feb 12, 2009 · Primary completion Oct 28, 2010
Drug: NSAID; tanezumab and 5 more · For: Osteoarthritis; Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 333 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective5,458
- off label use3,498
- fatigue3,409
- arthralgia3,339
- pain3,325
- nausea3,299
- diarrhoea2,965
- vomiting2,687
- rheumatoid arthritis2,594
- rash2,565
- headache2,487
- condition aggravated2,434
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 857 |
| 2005 | 679 |
| 2006 | 215 |
| 2007 | 349 |
| 2008 | 556 |
| 2009 | 465 |
| 2010 | 444 |
| 2011 | 658 |
| 2012 | 544 |
| 2013 | 465 |
| 2014 | 450 |
| 2015 | 1,302 |
| 2016 | 1,642 |
| 2017 | 1,740 |
| 2018 | 1,918 |
| 2019 | 2,365 |
| 2020 | 2,679 |
| 2021 | 2,689 |
| 2022 | 3,027 |
| 2023 | 2,739 |
| 2024 | 3,358 |
| 2025 | 4,089 |
| 2026 | 2,455 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Nissen SE, Yeomans ND, Solomon DH, et al. · N Engl J Med 2016 · Multicenter Study, Randomized Controlled Trial
- Rofecoxib for osteoarthritis.
Garner SE, Fidan DD, Frankish R, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Celecoxib for osteoarthritis.
Puljak L, Marin A, Vrdoljak D, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Systematic Review
- WITHDRAWN: Celecoxib for rheumatoid arthritis.
Garner SE, Fidan D, Frankish RR, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of hip abductors exercise training combined with repetitive transcranial magnetic stimulation on knee osteoarthritis: A randomized controlled trial.
Cheng C, Wang J, Yang K, et al. · Technol Health Care 2024 · Randomized Controlled Trial
- Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Obeid S, Libby P, Husni E, et al. · Eur Heart J Cardiovasc Pharmacother 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Carwin Pharm Assoc
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.